Koichiro Adachi, Katsuhiro Ohyama, Yoichi Tanaka, Yoshiro Saito, Makiko Shimizu, Hiroshi Yamazaki. Modeled Hepatic/Plasma Exposures of Fluvastatin Prescribed Alone in Subjects with Impaired Cytochrome P450 2C9*3 as One of Possible Determinant Factors Likely Associated with Hepatic Toxicity Reported in a Japanese Adverse Event Database. Biological & pharmaceutical bulletin. 2024. 47. 3. 635-640
Makiko Shimizu, Shotaro Uehara, Katsuhiro Ohyama, Haruka Nishimura, Yoichi Tanaka, Yoshiro Saito, Hiroshi Suemizu, Sayaka Yoshida, Hiroshi Yamazaki. Pharmacokinetic Models Scaled-up from Humanized-liver Mouse Data Can Account for Drug Monitoring Results of Atomoxetine and Its 4-Hydroxylated andN-Demethylated Metabolites in Pediatric Patients Genotyped for CytochromeP450 2D6. Drug Metabolism and Disposition. 2024. 52. 1. 35-43
Katsuhiro Ohyama, Shota Akiyama, Megumi Iida, Yusuke Hori. Association of Torsade de Pointes and QT Prolongation With Antifungal Triazoles: Analysis Using a Pharmacovigilance Database. In vivo (Athens, Greece). 2023. 37. 6. 2719-2725
Koichiro Adachi, Katsuhiro Ohyama, Yoichi Tanaka, Hina Nakano, Tasuku Sato, Norie Murayama, Makiko Shimizu, Yoshiro Saito, Hiroshi Yamazaki. Plasma and Hepatic Exposures of Celecoxib and Diclofenac Prescribed Alone in Patients with Cytochrome P450 2C9*3 Modeled after Virtual Oral Administrations and Likely Associated with Adverse Drug Events Reported in a Japanese Database. Biological & pharmaceutical bulletin. 2023. 46. 6. 856-863
Koichiro Adachi, Katsuhiro Ohyama, Yoichi Tanaka, Tasuku Sato, Norie Murayama, Makiko Shimizu, Yoshiro Saito, Hiroshi Yamazaki. High hepatic and plasma exposures of atorvastatin in subjects harboring impaired cytochrome P450 3A4∗16 modeled after virtual administrations and possibly associated with statin intolerance found in the Japanese adverse drug event report database. Drug metabolism and pharmacokinetics. 2023. 49. 100486-100486
